January 2025

UROLOGY

EVOLVING STRATEGIES IN BCG-UNRESPONSIVE BLADDER CANCER TREATMENT

Joshua J. Meeks, MD, PhD, discusses the pressing need to transition to robust randomized controlled trials for BCG-unresponsive bladder cancer patients. Reflecting on his presentation at SUO 2024, Dr. Meeks examines the current landscape of bladder cancer treatment, emphasizing the availability of multiple FDA-approved options, including Keytruda, Anktiva and Adstiladrin.
​
Dr. Meeks advocates for establishing direct comparisons among these therapies to improve clinical decision-making. He proposes a research framework focused on durable outcomes that uses standardized evaluation methods and incorporates biomarkers to guide treatment sequences.
Joshua J. Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD, Professor of Urology and Associate Professor of Urology and of Biochemistry and Molecular Genetics at Northwestern Medicine 

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like